• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

    2/13/24 9:10:56 AM ET
    $NVTA
    Medical Specialities
    Health Care
    Get the next $NVTA alert in real time by email
    SC 13G/A 1 ef20021446_sc13ga.htm SC 13G/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G
    Under the Securities Exchange Act of 1934
    (Amendment No. 4)*

    Invitae Corporation

    (Name of Issuer)

    Common stock, $0.0001 par value per share

    (Title of Class of Securities)

    46185L103

    (CUSIP Number)

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☒Rule 13d-1(b)

    ☐Rule 13d-1(c)

    ☐Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).



    CUSIP No.

    1
    NAMES OF REPORTING PERSONS
     
     
    Nikko Asset Management Americas, Inc.
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    USA
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    15,595,279
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    16,764,480
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    16,764,480
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    5.85%
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    IA
     
     
     
     


    Item 1.

     
    (a)
    Name of Issuer



       
    Invitae Corporation
         
     
    (b)
    Address of Issuer’s Principal Executive Offices
         
       
    1400 16th Street, San Francisco, CA 94103

    Item 2.

     
    (a)
    Name of Person Filing
         
       
    Nikko Asset Management Americas, Inc.
         
     
    (b)
    Address of Principal Business Office or, if none, Residence
       
     
       
    605 Third Avenue, 38th Floor, New York, NY 10158
         
     
    (c)
    Citizenship
         
       
    USA
         
     
    (d)
    Title of Class of Securities
         
       
    Common stock, $0.0001 par value per share
         
     
    (e)
    CUSIP Number
         
       
    46185L103

    Item 3.
    If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

     
    (a)
    ☐
    Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).
           
     
    (b)
    ☐
    Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).
           
     
    (c)
    ☐
    Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c).
           
     
    (d)
    ☐
    Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C 80a-8).
           
     
    (e)
    ☒
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
           
     
    (f)
    ☐
    An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
           
     
    (g)
    ☐
    A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
           
     
    (h)
    ☐
    A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
           
     
    (i)
    ☐
    A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
           
     
    (j)
    ☐
    A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J).
           
     
    (k)
    ☐
    A group, in accordance with § 240.13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:


    Item 4.
    Ownership.

    Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     
    (a)
    Amount beneficially owned:
           
         
    16,764,480
           
     
    (b)
    Percent of class:
           
         
    5.85%
           
     
    (c)
    Number of shares as to which the person has:
           
       
    (i)
    Sole power to vote or to direct the vote:
           
         
    0
           
       
    (ii)
    Shared power to vote or to direct the vote:
           
         
    15,595,279
           
       
    (iii)
    Sole power to dispose or to direct the disposition of:
           
         
    0
           
       
    (iv)
    Shared power to dispose or to direct the disposition of:
           
         
    16,764,480

    Item 5.
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.

    Item 6.
    Ownership of More than Five Percent on Behalf of Another Person.

    See Exhibit A.

    Item 7.
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company

    See Exhibit A.

    Item 8.
    Identification and Classification of Members of the Group

    Not Applicable.

    Item 9.
    Notice of Dissolution of Group

    Not Applicable.

    Item 10.
    Certification

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: February 12, 2024
    By:
    /s/ Gary L. Beckham
       
    Name: Gary L. Beckham
       
    Title: Chief Compliance Officer

    Attention:
    Intentional misstatements or omissions of fact constitute Federal criminal violations (See 18 U.S.C. 1001)


    Exhibit A

    Pursuant to the instructions in Items 6 and 7 of Schedule 13G, the security being reported on by Nikko Asset Management Americas, Inc., as subsidiary to the parent holding companies listed below, are owned, or may be deemed to be beneficially owned, by its parent holding companies.


    1)
    Sumitomo Mitsui Trust Holdings Inc.

    o
    A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);

    o
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).


    2)
    Nikko Asset Management Co., Ltd.

    o
    An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);

    o
    A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J).



    Get the next $NVTA alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $NVTA

    DatePrice TargetRatingAnalyst
    7/5/2023Underweight
    JP Morgan
    5/15/2023Mkt Perform → Underperform
    Raymond James
    1/31/2023$2.00Neutral → Sell
    Goldman
    8/25/2022$1.00Underperform
    Credit Suisse
    8/10/2022Neutral → Underweight
    JP Morgan
    7/26/2022$8.00 → $2.50Outperform → Market Perform
    Cowen
    7/21/2022Outperform → Mkt Perform
    Raymond James
    7/20/2022Buy → Neutral
    Ladenburg Thalmann
    More analyst ratings

    $NVTA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Labcorp Announces Winning Bid for Select Assets of Invitae

      Advances Labcorp strategy to launch and scale specialty testing in areas such as oncology and rare diseases Transaction requires court approval, with confirmation expected on May 6, 2024 BURLINGTON, N.C., April 24, 2024 /PRNewswire/ -- Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, announced today that it has been selected as the winning bidder for select assets of Invitae, a leading medical genetics company.  Before the transaction can proceed, the court overseeing the process must issue an approval order following a hearing currently scheduled for May 6, 2024.

      4/24/24 9:27:00 PM ET
      $LH
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Enters into Agreement with Labcorp for Sale of Business

      – Labcorp Selected as Winning Bidder in Court-Supervised Sale Process, Subject to Court and Regulatory Approvals – – $239 Million Cash Bid Includes Acquisition of Substantially All of the Company's Assets, Ensuring Business Continuity for Customers, Partners and Employees – SAN FRANCISCO, April 24, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, announced that Labcorp (NYSE:LH), a global leader of innovative and comprehensive laboratory services, has been selected as the winning bidder in the Company's auction in its sale process under Section 363 of the U.S. Bankruptcy Code. Labcorp will acquire substantially all of the Company's assets on a going concern basis

      4/24/24 9:19:00 PM ET
      $LH
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Publishes its Environmental, Social and Governance (ESG) Report

      – Report details the company's commitment to improving healthcare through the power of genetic information and discloses Environmental, Social and Governance initiatives for fiscal year 2023 – SAN FRANCISCO, April 22, 2024 /PRNewswire/ -- Invitae (OTC:NVTA), a leading medical genetics company, today published its 2024 Environmental, Social and Governance (ESG) Report. This report provides a holistic view of the company's approach to ESG and its performance and progress through measurable data and metrics during the 2023 fiscal year. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring c

      4/22/24 12:43:00 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Leadership Updates

    Live Leadership Updates

    See more
    • Aranscia Acquires YouScript from Invitae

      Pioneering Pharmacogenomics Platform Joins Portfolio of Complementary Precision Medicine Workflow Solutions Aranscia, a global provider of diagnostics software, services, and testing solutions, and Invitae Corporation, a leading medical genetics company, today announced that Aranscia has acquired select assets of the YouScript personalized medication management platform from Invitae Corporation in an all-cash transaction. YouScript is a widely recognized leader in providing actionable, real-time medication risk and pharmacogenomics (PGx) insights that enable healthcare providers and organizations to build, deliver, and scale comprehensive personalized medication management programs. YouSc

      11/15/23 4:35:00 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Announces Appointment of Finance Veteran Ana Schrank as CFO

      SAN FRANCISCO, Sept. 25, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced the appointment of finance veteran Ana Schrank as the Company's chief financial officer (CFO), effective October 2. Robert Dickey, who has been the Company's interim CFO since August 2023, will transition to a consulting role for the Company and will work closely with Ms. Schrank and the leadership team to ensure a smooth transition.  www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the qu

      9/25/23 4:30:00 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Hires Industry Veteran Robert Guigley as Chief Commercial Officer

      – Invitae adds chief commercial officer to leadership team; Innovative leader to help expand market share and drive revenue growth –  SAN FRANCISCO, Aug. 28, 2023  /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it has appointed Robert (Rob) Guigley as its chief commercial officer, effective September 5, 2023. Mr. Guigley brings to the role more than 20 years of commercial experience spanning biotechnology, pharmaceuticals, diagnostics and genetic testing. He will develop and implement Invitae's commercial strategy with a focus on driving profitable revenue growth, expanding the market, improving reimbursement levels and enhancing the service of

      8/28/23 4:02:00 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    SEC Filings

    See more
    • SEC Form 25-NSE filed by Invitae Corporation

      25-NSE - Invitae Corp (0001501134) (Subject)

      2/21/24 8:59:54 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Events That Accelerate or Increase a Direct Financial Obligation, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

      8-K - Invitae Corp (0001501134) (Filer)

      2/14/24 6:59:56 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Corporation filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

      8-K - Invitae Corp (0001501134) (Filer)

      2/6/24 5:07:32 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Financials

    Live finance-specific insights

    See more
    • Natera Acquires Reproductive Health Assets from Invitae

      Natera, Inc. (NASDAQ:NTRA), a global leader in cell-free DNA (cfDNA) testing, today announced that it has acquired from Invitae (NYSE:NVTA), a leading medical genetics company, certain assets relating to Invitae's non-invasive prenatal screening and carrier screening business. Natera has made an upfront payment in the amount of $10 million to Invitae. In addition, the transaction includes $42.5 million in potential milestone payments including cash and litigation-related credits. Pursuant to the agreement, Invitae will transition its non-invasive prenatal screening and carrier screening customers to Natera. "We are committed to providing excellent service, and we look forward to the o

      1/22/24 7:00:00 AM ET
      $NTRA
      $NVTA
      Medical Specialities
      Health Care
    • Invitae Reports Second Quarter 2023 Financial Results

      – Reported revenue of $120.5 million, a 12% year-over-year decrease due to exited businesses and geographies; pro forma revenue up slightly year-over-year –  – GAAP gross margin was 27.4% and non-GAAP gross margin was 49.8%; continued improvement in non-GAAP gross margin for eight consecutive quarters – – Company improves ongoing cash burn annual guidance to $220-$245 million; adjusts 2023 revenue guidance to $480-$500 million from over $500 million previously – – Conference call and webcast today at 4:30 p.m. Eastern Time / 1:30 p.m. Pacific Time – SAN FRANCISCO, Aug. 8, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced financial and operating res

      8/8/23 4:01:00 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae to Announce Second Quarter 2023 Financial Results on Tuesday, August 8, 2023

      SAN FRANCISCO, July 26, 2023 /PRNewswire/ -- Invitae (NYSE:NVTA), a leading medical genetics company, today announced that it will report its second quarter 2023 financial results on Tuesday, August 8, 2023, and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m. Pacific to discuss its financial results and recent highlights. www.invitae.com (PRNewsFoto/Invitae Corporation)" alt="Invitae's (NVTA) mission is to bring comprehensive genetic information into mainstream medical practice to improve the quality of healthcare for billions of people. www.invitae.com (PRNewsFoto/Invitae Corporation)">

      7/26/23 4:01:00 PM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

      SC 13G/A - Invitae Corp (0001501134) (Subject)

      2/13/24 5:07:58 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

      SC 13G/A - Invitae Corp (0001501134) (Subject)

      2/13/24 9:10:56 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • SEC Form SC 13G/A filed by Invitae Corporation (Amendment)

      SC 13G/A - Invitae Corp (0001501134) (Subject)

      2/5/24 6:08:57 AM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • JP Morgan resumed coverage on Invitae

      JP Morgan resumed coverage of Invitae with a rating of Underweight

      7/5/23 7:28:43 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae downgraded by Raymond James

      Raymond James downgraded Invitae from Mkt Perform to Underperform

      5/15/23 7:28:13 AM ET
      $NVTA
      Medical Specialities
      Health Care
    • Invitae downgraded by Goldman with a new price target

      Goldman downgraded Invitae from Neutral to Sell and set a new price target of $2.00

      1/31/23 6:15:23 AM ET
      $NVTA
      Medical Specialities
      Health Care

    $NVTA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nussbaum Robert L covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 3% to 551,941 units (SEC Form 4)

      4 - Invitae Corp (0001501134) (Issuer)

      12/21/23 9:20:16 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Brida Thomas covered exercise/tax liability with 17,404 shares, decreasing direct ownership by 2% to 916,183 units (SEC Form 4)

      4 - Invitae Corp (0001501134) (Issuer)

      12/21/23 9:14:33 PM ET
      $NVTA
      Medical Specialities
      Health Care
    • Sholehvar David was granted 850,000 shares (SEC Form 4)

      4 - Invitae Corp (0001501134) (Issuer)

      11/14/23 7:58:49 PM ET
      $NVTA
      Medical Specialities
      Health Care